

10084676

=> d his


(FILE 'HOME' ENTERED AT 10:57:02 ON 02 JAN 2003)

FILE 'REGISTRY' ENTERED AT 10:57:11 ON 02 JAN 2003

L1 0 S DICLOPHENAC/CN  
L2 1 S DICLOPHENAC  
L3 1 S DICLOFENAC/CN

=> d l3

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS  
RN 15307-86-5 REGISTRY  
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (9CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Acetic acid, [o-(2,6-dichloroanilino)phenyl]- (8CI)  
OTHER NAMES:  
CN 2-(2,6-Dichloroanilino)phenylacetic acid  
CN 2-(2,6-Dichlorophenylamino)phenylacetic acid  
CN 2-[(2,6-Dichlorophenyl)amino]benzeneacetic acid  
CN Dichlofenac  
CN **Diclofenac**  
CN Diclofenac acid  
CN Dicloreauma  
CN N-(2,6-Dichlorophenyl)-o-aminophenylacetic acid  
CN Pennsaid  
CN Transfenac  
CN [o-(2,6-Dichloroanilino)phenyl]acetic acid  
DR 76595-40-9, 87180-41-4  
MF C14 H11 Cl2 N O2  
CI COM  
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*,  
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB,  
CEN, CHEMCATS, CHEMLIST, CIN, CSCHM, CSNB, DDFU, DIOGENES, DRUGPAT,  
DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK\*, PHAR,  
PHARMASEARCH, PROMT, RTECS\*, SPECINFO, TOXCENTER, ULIDAT, USAN, USPAT2,  
USPATFULL, VETU  
(\*File contains numerically searchable property data)  
Other Sources: EINECS\*\*, WHO  
(\*\*Enter CHEMLIST File for up-to-date regulatory information)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2646 REFERENCES IN FILE CA (1962 TO DATE)  
94 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
2654 REFERENCES IN FILE CAPLUS (1962 TO DATE)

blessing

10084676

=> d 12

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS  
RN 15307-79-6 REGISTRY  
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, monosodium salt (9CI)  
(CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Acetic acid, [o-(2,6-dichloroanilino)phenyl]-, monosodium salt (8CI)

OTHER NAMES:

CN 2-(2,6-Dichloroanilino)phenylacetic acid sodium salt  
CN Diclofen SR 100  
CN Diclofenac sodium  
CN Diclofenac sodium salt  
CN **Diclophenac sodium**  
CN Diklovit  
CN Feloran  
CN GP 45840  
CN Hyanalgesa D  
CN Inflanban  
CN N-(2,6-Dichlorophenyl)-o-aminophenylacetic acid sodium salt  
CN Naclof  
CN Orthofen  
CN Orthophen  
CN Sodium diclofenac  
CN Sodium [o-(2,6-dichloroanilino)phenyl]acetate  
CN Sorelmon  
CN SR 318B  
CN Voltaren  
CN Voltaren Ophtha  
CN Voltaren Ophtha CD  
CN Voltarol  
CN [o-(2,6-Dichloroanilino)phenyl]acetic acid sodium salt  
MF C14 H11 Cl2 N O2 . Na  
CI COM


LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*,  
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CEN,  
CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGPAT, DRUGU, EMBASE,  
IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK\*, MSDS-OHS, NIOSHTIC, PHAR,  
PHARMASEARCH, PIRA, PROMT, RTECS\*, TOXCENTER, ULIDAT, USAN, USPAT2,  
USPATFULL

(\*File contains numerically searchable property data)

Other Sources: DSL\*\*, EINECS\*\*

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

CRN (15307-86-5)



● Na

blessing

10084676

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1614 REFERENCES IN FILE CA (1962 TO DATE)

17 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

1619 REFERENCES IN FILE CAPLUS (1962 TO DATE)

blessing



☐ [Generate Collection](#) [Print](#)

L3: Entry 101 of 179

File: USPT

Sep 25, 2001

DOCUMENT-IDENTIFIER: US 6294195 B1

TITLE: Orally administrable opioid formulations having extended duration of effect

Detailed Description Text (2):

The multiparticulate systems of the present invention may incorporate one or more compounds known as opioid analgesics. Opioid analgesic compounds which may be used in the present invention include alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, cyclazocine, desomorphine, dextromoramide, dezocine, diampromide, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene fentanyl, heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levallorphan, levorphanol, levophenacymorphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, nalbuphine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propiram, propoxyphene, sufentanil, tramadol, tilidine, salts thereof, mixtures of any of the foregoing, mixed mu-agonists/antagonists, mu-antagonist combinations, and the like.

Detailed Description Text (7):

The substrates of the present invention may further include one or more additional drugs which may or may not act synergistically with the opioid analgesics of the present invention. Examples of such additional drugs include non-steroidal anti-inflammatory agents, including ibuprofen, diclofenac, naproxen, benoxaprofen, flurbiprofen, fenoprofen, flubufen, ketoprofen, indoprofen, piroprofen, carprofen, oxaprozin, pramoprofen, muprofen, trioxaprofen, suprofen, aminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac, oxpinac, mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, tolfenamic acid, diflurisal, flufenisal, piroxicam, sudoxicam or isoxicam, and the like. Other suitable additional drugs which may be included in the dosage forms of the present invention include acetaminophen, aspirin, and other non-opioid analgesics.

Other Reference Publication (17):

Abraham Sunshine, et al., "Analgesic oral efficacy of tramadol hydrochloride in postoperative pain", Clin. Pharmacol. Ther., Jun. 1992, pp. 740-746.

## CLAIMS:

5. The dosage form of claim 1, wherein said opioid analgesic is selected from the group consisting of morphine, codeine, hydromorphone, hydrocodone, oxycodone, oxymorphone, dihydrocodeine, dihydromorphine, tramadol, and mixtures thereof.

6. The dosage form of claim 1, wherein said opioid analgesic is selected from the group consisting of alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, cyclazocine, desomorphine, dextromoramide, dezocine, diampromide, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene fentanyl, heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levallorphan, levorphanol, levophenacyl morphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, nalbuphine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, normorphine, norpipanone,

opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propiram, propoxyphene, sufentanil, tramadol, tilidine, salts thereof and mixtures thereof.

16. A bioavailable sustained-release oral analgesic dosage form for once-a-day administration, comprising:

a unit dose comprising a plurality of pharmaceutically acceptable matrices comprising an analgesically effective amount of tramadol or a salt thereof, ethylcellulose and stearyl alcohol, each of said matrices having a diameter from about 0.1 mm to about 3 mm, said dosage form being bioavailable and providing a therapeutic effect for about 24 hours or more after oral administration to a human patient.

20. The dosage form of claim 19, wherein said non-steroidal anti-inflammatory agent is selected from the group consisting of ibuprofen, diclofenac, naproxen, benoxaprofen, flurbiprofen, fenoprofen, flubufen, ketoprofen, indoprofen, piroprofen, carprofen, oxaprozin, pramoprofen, muprofen, trioxaprofen, suprofen, aminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acetamin, fentiazac, clidanac, oxpinac, mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, tolfenamic acid, diflurisal, flufenisal, piroxicam, sudoxicam or isoxicam, and mixtures of any of the foregoing.

21. The dosage form of claim 1, wherein said opioid analgesic consists of tramadol or a salt thereof.

**WEST**

Generate Collection

Print

L3: Entry 101 of 179

File: USPT

Sep 25, 2001

US-PAT-NO: 6294195

DOCUMENT-IDENTIFIER: US 6294195 B1

TITLE: Orally administrable opioid formulations having extended duration of effect

DATE-ISSUED: September 25, 2001

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Oshlack; Benjamin	New York	NY		
Chasin; Mark	Manalapan	NJ		

US-CL-CURRENT: 424/457; 424/456, 424/484, 424/486, 424/487, 424/488, 424/489,  
514/772.3, 514/781, 514/951

## CLAIMS:

What is claimed is:

1. A bioavailable sustained-release oral analgesic dosage form for once-a-day administration, comprising:

a unit dose comprising an analgesically effective amount of a plurality of pharmaceutically acceptable matrices comprising an opioid analgesic or a salt thereof, and a hydrophobic material selected from the group consisting of an alkylcellulose, an acrylic resin and mixtures thereof, said matrices further comprising at least one C.sub.12 to C.sub.36 aliphatic alcohol, each of said matrices having a diameter from about 0.1 mm to about 3 mm, said dosage form being bioavailable and providing a therapeutic effect for about 24 hours or more after oral administration to a human patient.

2. A bioavailable sustained-release oral analgesic dosage form for once-a-day administration, comprising:

a unit dose comprising a plurality of pharmaceutically acceptable matrices comprising an analgesically effective amount of hydromorphone or a salt thereof, ethylcellulose and stearyl alcohol, each of said matrices having a diameter from about 0.1 mm to about 3 mm, said dosage form being bioavailable and providing a therapeutic effect for about 24 hours or more after oral administration to a human patient.

3. The dosage form of claim 1, wherein said matrices further comprise at least one polyalkylene glycol.

4. The dosage form of claim 1, wherein said C.sub.12 to C.sub.36 aliphatic alcohol is stearyl alcohol.

5. The dosage form of claim 1, wherein said opioid analgesic is selected from the group consisting of morphine, codeine, hydromorphone, hydrocodone, oxycodone, oxymorphone, dihydrocodeine, dihydromorphone, tramadol, and mixtures thereof.

6. The dosage form of claim 1, wherein said opioid analgesic is selected from the group consisting of alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, cyclazocine, desomorphine, dextromoramide, dezocine, diampromide, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene fentanyl, heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levallorphan, levorphanol, levophenacyl morphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, nalbuphine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propiram, propoxyphene, sufentanil, tramadol, tilidine, salts thereof and mixtures thereof.
7. The dosage form of claim 5, wherein said opioid analgesic consists of from about 2 mg to about 64 mg hydromorphone.
8. The dosage form of claim 5, wherein said opioid analgesic consists of from about 5 mg to about 800 mg morphine.
9. The dosage form of claim 1, wherein said opioid analgesic consists of from about 5 mg to about 400 mg oxycodone.
10. The dosage form of claim 1 which provides a peak plasma level of said opioid in-vivo from about 2 to about 10 hours after administration.
11. The dosage form of claim 1 which provides a peak plasma level of said opioid in-vivo from about 2 to about 4 hours after administration.
12. The dosage form of claim 1, wherein said matrices further comprise a hydroxyalkylcellulose selected from the group consisting of hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose and mixtures of any of the foregoing.
13. The dosage form of claim 12, wherein said hydroxyalkylcellulose is hydroxyethylcellulose.
14. The dosage form of claim 1, wherein said unit dose of said matrices are contained within a hard gelatin capsule.
15. The dosage form of claim 1, wherein said matrices have a diameter from about 0.5 mm to about 2 mm.
16. A bioavailable sustained-release oral analgesic dosage form for once-a-day administration, comprising:  
  
a unit dose comprising a plurality of pharmaceutically acceptable matrices comprising an analgesically effective amount of tramadol or a salt thereof, ethylcellulose and stearyl alcohol, each of said matrices having a diameter from about 0.1 mm to about 3 mm, said dosage form being bioavailable and providing a therapeutic effect for about 24 hours or more after oral administration to a human patient.
17. The dosage form of claim 1, further comprising release-modifying agents, said release-modifying agents comprising one or more hydrophilic polymers.
18. A dosage form of claim 1, further comprising a non-opioid drug.
19. The dosage form of claim 18, wherein the said non-opioid drug is a non-steroidal anti-inflammatory agent.

20. The dosage form of claim 19, wherein said non-steroidal anti-inflammatory agent is selected from the group consisting of ibuprofen, diclofenac, naproxen, benoxaprofen, flurbiprofen, fenoprofen, flubufen, ketoprofen, indoprofen, piroprofen, carprofen, oxaprozin, pramoprofen, muprofen, trioxaprofen, suprofen, aminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acetaminophen, fentiazac, clidanac, oxpinac, mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, tolafenamic acid, diflunisal, flufenisal, piroxicam, sudoxicam or isoxicam, and mixtures of any of the foregoing.

21. The dosage form of claim 1, wherein said opioid analgesic consists of tramadol or a salt thereof.

22. The dosage form of claim 1, wherein said alkylcellulose is ethylcellulose.

23. The dosage form of claim 2 which provides a peak plasma level of said opioid in-vivo from about 2 to about 10 hours after administration to a patient or a population of patients.

24. The dosage form of claim 2 which provides a peak plasma level of said opioid in-vivo from about 2 to about 4 hours after administration to a patient or a population of patients.

25. The dosage form of claim 16 which provides a peak plasma level of said opioid in-vivo from about 2 to about 10 hours after administration to a patient or a population of patients.

26. The dosage form of claim 16 which provides a peak plasma level of said opioid in-vivo from about 2 to about 4 hours after administration to a patient or a population of patients.



**WEST**

Generate Collection

Print

L3: Entry 89 of 179

File: USPT

Aug 20, 2002

US-PAT-NO: 6436438

DOCUMENT-IDENTIFIER: US 6436438 B1

TITLE: Tramadol multiple unit formulations

DATE-ISSUED: August 20, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Momberger; Helmut	Marburg			DE
Raber; Marc	Giessen			DE
Kuhn; Dieter	Marburg			DE
Schmid; Wolfgang	Lohra			DE

## ASSIGNEE-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY	TYPE CODE
Asto-Medica AG	Radebeul			DE	03

APPL-NO: 09/ 349564 [PALM]

DATE FILED: July 8, 1999

## PARENT-CASE:

This application is a Divisional of Ser. No. 08/896,629 filed Jul. 18, 1997 now U.S. Pat. No. 5,955,104.

## FOREIGN-APPL-PRIORITY-DATA:

COUNTRY	APPL-NO	APPL-DATE
DE	196 30 035	July 25, 1996

INT-CL: [07] A61 K 9/22, A61 K 9/54, A61 K 9/60, A61 K 9/62

US-CL-ISSUED: 424/458; 424/457, 424/459, 424/461, 424/462, 424/468, 424/494, 424/495, 424/496, 424/497, 514/770, 514/781, 514/782, 514/951

US-CL-CURRENT: 424/458; 424/457, 424/459, 424/461, 424/462, 424/468, 424/494, 424/495, 424/496, 424/497, 514/770, 514/781, 514/782, 514/951

FIELD-OF-SEARCH: 424/472, 424/458, 424/459, 424/461, 424/462, 424/494, 424/495, 424/497, 424/457, 424/468, 424/496, 424/456, 424/469, 424/470

## PRIOR-ART-DISCLOSED:

U.S. PATENT DOCUMENTS

Search Selected

Search ALL

	PAT-NO	ISSUE-DATE	PATENTEE-NAME	US-CL
<input type="checkbox"/>	<u>5026560</u>	June 1991	Makino et al.	424/494
<input type="checkbox"/>	<u>5344657</u>	September 1994	Desmolin	424/458
<input type="checkbox"/>	<u>5478577</u>	December 1995	Sackler et al.	424/489
<input type="checkbox"/>	<u>5567441</u>	October 1996	Chen	424/494
<input type="checkbox"/>	<u>5955104</u>	September 1999	Momberger et al.	424/458

ART-UNIT: 1615

PRIMARY-EXAMINER: Spear; James M.

## ABSTRACT:

A multiple unit oral pharmaceutical dosage form having a plurality of pellets in a water soluble capsule or in a tablet compressed from the pellets, wherein each pellet contains (a) a substantially inert core, (b) an active ingredient layer over the inert core, and containing (i) a pharmacologically active particulate active ingredient, (ii) a nonembedding amount of a binder for adhering the active ingredient over the inert core, and optionally (iii) a pharmaceutically acceptable, inert adjuvant, such as colloidal silica, and (c) a coating over the active ingredient layer for retarding the release of the active ingredient from the active ingredient layer into an aqueous body fluid solvent in situ, the nonembedding amount of the binder is suitably from about 1% wt. to about 10% wt. based on the active ingredient layer, the binder in the active ingredient layer is suitably a mixture of ethylcellulose and shellac, in a weight proportion suitably of from about 1: about 9, to from about 9: about 1, the coating for retarding the release suitably contains from about 70% wt. to about 95% wt. based on the coating, of a substantially water-insoluble, pharmacologically inert, particulate material, and a binder; the pharmacologically inert, particulate material is suitably talcum, and the binder in the active ingredient layer is suitably identical to the binder in the coating.

20 Claims, 7 Drawing figures

**WEST**

Generate Collection

Print

L2: Entry 15 of 16

File: USPT

Sep 22, 1998

DOCUMENT-IDENTIFIER: US 5811459 A

TITLE: Ortho substituted aromatic compounds useful as antagonists of the pain enhancing effects of E-type prostaglandins

Brief Summary Text (3):

Non-steroidal anti-inflammatory drugs (NSAIDS) and opiates are the main classes of drugs in pain relief. However both possess undesirable side effects. NSAIDS are known to cause gastrointestinal irritation and opiates are known to be addictive.

Brief Summary Text (4):

We have now found a class of compounds structurally different to NSAIDS and opiates, and useful in the relief of pain.

Brief Summary Text (201):

By virtue of their ability to relieve pain, the compounds of the formula I are of value in the treatment of certain inflammatory and non-inflammatory conditions which are currently treated with a cyclooxygenase-inhibitory non-steroidal anti-inflammatory drug (NSAID) such as indomethacin, ketorolac, acetylsalicylic acid, ibuprofen, sulindac, tolmetin and piroxicam or other analgesics such as paracetamol, tramadol, Codein or in some circumstances morphine. Co-administration of a compound of the formula I with a NSAID can result in a reduction of the quantity of the latter agent needed to produce a therapeutic effect. Thereby the likelihood of adverse side-effects from the NSAID such as gastrointestinal effects are reduced. Thus according to a further feature of the invention there is provided a pharmaceutical composition which comprises a compound of the formula (I), or an in-vivo hydrolysable ester or amide or pharmaceutically-acceptable salt thereof, in conjunction or admixture with a cyclooxygenase inhibitory non-steroidal anti-inflammatory agent, and a pharmaceutically-acceptable diluent or carrier.

Detailed Description Text (30):

b:- (4-Carboxymethylphenylmethyl)triphenylphosphonium bromide prepared in the standard way from 4-(bromomethyl)phenylacetic acid and triphenylphosphine.

Detailed Description Paragraph Table (2):

##STR26##

Compd Foot- No. R1 Link R2 m.p. note

CH.sub.2	CO.sub.2	H 143-144	a 2	H	CH.sub.2	CH.sub.2	CH.sub.2	CO.sub.2	H 88-89	b 3	5-Cl	
CH.sub.2	CH.sub.2	CH.sub.2	CO.sub.2	H 91-92	b 4	5-F	CH.sub.2	CH.sub.2	CH.sub.2	CO.sub.2		
H 102-103	5	5-Cl	CH.sub.2	CH.sub.2	CH.sub.2	CO.sub.2	H 95.5-96.5	6	5-OMe	CH.sub.2		
CH.sub.2	CH.sub.2	CO.sub.2	H 102-103	7	6-OMe	CH.sub.2	CH.sub.2	CH.sub.2	CO.sub.2	H		
90-91	8	4-OMe	CH.sub.2	CH.sub.2	CH.sub.2	CO.sub.2	H 121-121.5	9	6-F	CH.sub.2	CH.sub.2	
CH.sub.2	CO.sub.2	H 92-93	10	3,5-diCl	CH.sub.2	CH.sub.2	CH.sub.2	CO.sub.2	H 163-163.5			
11	5-NO	sub.2	CH.sub.2	CH.sub.2	CH.sub.2	CO.sub.2	H 161-163	c 12	5-NH	sub.2	CH.sub.2	
CH.sub.2	CH.sub.2	CO.sub.2	H 152-155	d 13	5-NHCO	CH.sub.2	CH.sub.2	CH.sub.2	CO.sub.2			
H 181-183	e 14	5-NHCO	sub.2	Et	CH.sub.2	CH.sub.2	CH.sub.2	CO.sub.2	H 165-167	f 15		
5-NHSO	sub.2	Ph	CH.sub.2	CH.sub.2	CH.sub.2	CO.sub.2	H 159-161	g 16	5-NHMe	CH.sub.2		
CH.sub.2	CH.sub.2	CO.sub.2	H 153-154	h 17	5-NEt	sub.2	CH.sub.2	CH.sub.2	CH.sub.2			
CO.sub.2	H 67-68	i 18	5-COMe	CH.sub.2	CH.sub.2	CH.sub.2	CO.sub.2	H 147-147.5	j 19			
5-CO-nPentyl	CH.sub.2	CH.sub.2	CH.sub.2	CO.sub.2	H 136-136.5	k 20	5-n-Hexyl	CH.sub.2				
CH.sub.2	CH.sub.2	CO.sub.2	H 91.5-92	l 21	5-Br	CH.sub.2	CH.sub.2	CH.sub.2	CO.sub.2	H		
115-118	m 22	5-CN	CH2CH2CH2	CO.sub.2	H 134-135	n 23	5-CHO	CH.sub.2	CH.sub.2	CH	CO.sub.2	
H 126-127	o 24	5-CH	sub.2	OH	CH.sub.2	CH.sub.2	CH.sub.2	CO.sub.2	H 102-103	p 25		
5-C(NOH)Me	CH.sub.2	CH.sub.2	CH.sub.2	CO.sub.2	H 166.5-167.5	q 26	5-C(NOH)H	CH	sub.2			
CH.sub.2	CH.sub.2	CO.sub.2	H 143.5-144	r 27	5-C(NOMe)Me	CH.sub.2	CH.sub.2	CH	sub.2			

CO.sub.2 H 121-122 s 28 5-Cl CH.sub.2 CH.sub.2 CO.sub.2 H 145-147 a 29 5-NO.sub.2  
 CH.sub.2 CH.sub.2 CO.sub.2 H 183-184 a,t 30 5-SOMe CH.sub.2 CH.sub.2 CH.sub.2 CO.sub.2  
 H 101-102 u 31 5-SO.sub.2 Me CH.sub.2 CH.sub.2 CH.sub.2 CO.sub.2 H 185 v 32 H CH.sub.2  
 CH.sub.2 CH.sub.2 CONHCH.sub.2 CO.sub.2 H 101-102 w 33 H CH.sub.2 CH.sub.2 CH.sub.2  
 CONH(CH.sub.2).sub.2 CO.sub.2 115-116 x 34 5,6-CHCHCHCH CH.sub.2 CH.sub.2 CH.sub.2  
 CO.sub.2 H 128-130 35 5,6-(CH.sub.2).sub.4 CH.sub.2 CH.sub.2 CH.sub.2 CO.sub.2 H  
 138-139 y 36 3-NO.sub.2 CH.sub.2 CH.sub.2 CH.sub.2 CO.sub.2 H 117-119 37  
 5-C(O)CHMe.sub.2 (CH.sub.2).sub.3 CO.sub.2 H 135-137 z 38 5-C(NO)CHMe.sub.2  
 (CH.sub.2).sub.3 CO.sub.2 H 170-176 (aa) 39 5-COEt (CH.sub.2).sub.3 CO.sub.2 H 116-118  
 (ab) 40 5-COPh (CH.sub.2).sub.3 CO.sub.2 H 142-144 (ac) 41 5-C(NO)Et (CH.sub.2).sub.3  
 CO.sub.2 H 168-170 (aa) 42 5-C(NO)Ph (CH.sub.2).sub.3 CO.sub.2 H 180-189 (aa) 43  
 5-C(NNHCONH.sub.2)CH.sub.3 (CH.sub.2).sub.3 CO.sub.2 H 158-160 (ad) 44  
 5-C(NHNH.sub.2)CH.sub.3 (CH.sub.2).sub.3 CO.sub.2 H 174-180 (ae) 45 5-C(NHNHPh)CH.sub.3  
 (CH.sub.2).sub.3 CO.sub.2 H 143-147 (af) 46 5-CH.sub.2 OMe (CH.sub.2).sub.3 CO.sub.2 H  
 81-84 (ag) 47 5-CH.sub.2 SMe (CH.sub.2).sub.3 CO.sub.2 H 107.5-111 (ah) 48 5-CH.sub.2  
 SO.sub.2 Me (CH.sub.2).sub.3 CO.sub.2 H 159.5-164 (ai) 49 5-CH.sub.2 SOME  
 (CH.sub.2).sub.3 CO.sub.2 H 137.5-140.5 (ai) 50 ##STR27## (CH.sub.2).sub.3 CO.sub.2 H  
 177.5-181.5 (aj) 51 5-NEt.sub.2 (CH.sub.2).sub.3 CO.sub.2 H 67-68 (ak) 52 5-Br  
 (CH.sub.2).sub.2 CO.sub.2 H 166-167 (al)

a:

(4-Carboxyphenylmethyl)triphenylphosphonium bromide was prepared in the standard way  
 from 4-(bromomethyl)benzoic acid and triphenylphosphine. b:  
 (4-Carboxymethylphenylmethyl)triphenylphosphonium bromide was prepared in the standard  
 way from 4-(bromomethyl)phenylacetic acid and triphenylphosphine. c: Methyl  
 4-[3-(2-hydroxy-5-nitrophenyl)propyl]benzoate was prepared from methyl  
 4-[3-(2-hydroxyphenyl)propyl]benzoate (see Example 1) as follows: Nitric acid (15M,  
 3.13 ml) was added to acetic anhydride (12.52 ml) at 0.degree. C. and the mixture  
 stirred for 15 minutes, then added to a stirred solution of methyl 4-[3-(2-hydroxy-  
 phenyl)propyl]benzoate (12.89 g) in acetic anhydride (300 ml) at 0.degree. C. and  
 stirred for 18 hours. The solvent was evaporated and the resulting yellow oil purified  
 by chromatography on silica gel using ethyl acetate:hexane (1:9 to 1:1 gradient) as  
 eluant to give methyl 4-[3-(2-hydroxy-3-nitrophenyl)propyl]benzoate (5.4 g) and methyl  
 4-[3-(2-hydroxy-5-nitro-phenyl)propyl]benzoate (7.5 g). d: Methyl  
 4-[3-(2-benzyloxy-5-aminophenyl)propyl]benzoate was prepared from methyl  
 4-[3-(2-benzyloxy-5-nitrophenyl)propyl]benzoate using the process described in Example  
 2, note a. e: Methyl 4-[3-(2-benzyloxy-5-methylcarbonylaminophenyl)propyl]benzoate was  
 prepared from methyl 4-[3-(2-benzyloxy-5-aminophenyl)-propyl]benzoate by the method  
 described in Example 2, note b.

**WEST**

Generate Collection

Print

L3: Entry 20 of 179

File: PGPB

Sep 19, 2002

PGPUB-DOCUMENT-NUMBER: 20020132850

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020132850 A1

TITLE: Multilayer tablet for administering a fixed combination of tramadol and diclofenac

PUBLICATION-DATE: September 19, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bartholomaeus, Johannes	Aachen		DE	
Ziegler, Iris	Rott-Roetgen		DE	

US-CL-CURRENT: 514/567; 424/472, 514/649